⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11778128 | 0.85 | TSHR (0.31) | — | |
| SCHEMBL25253322 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL15213128 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL3851887 | 0.79 | AKR1B1 (0.31) | — | |
| SCHEMBL127505 | 0.78 | SLC6A2 (0.31) | — | |
| SCHEMBL1044479 | 0.78 | — | — | |
| SCHEMBL555028 | 0.78 | — | — | |
| SCHEMBL8235057 | 0.78 | — | — | |
| SCHEMBL2226688 | 0.76 | — | — | |
| SCHEMBL17130439 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774122-B2 | ERG targeted therapy | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3600371-A1 | ERG TARGETED THERAPY | The Regents of The University of Michigan (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20180273595-A1 | ERG TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-09-27 | — | — | US | disclosed |
| WO-2018175273-A1 | ERG TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20150314065-A1 | Methods and Devices for Delivering GLP-1 and Uses Thereof | VALERITAS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9089636-B2 | Methods and devices for delivering GLP-1 and uses thereof | VALERITAS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2181712-A1 | Use of glucagon-like peptide-1 or analogs to abolish catabolic changes after surgery | Eli Lilly & Company (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1115421-B1 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF STROKE | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-0964873-B1 | USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY | LILLY CO ELI (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-0964692-B1 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION | LILLY CO ELI (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2000016797-A2 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF STROKE | ELI LILLY AND COMPANY (US) | 2000-03-30 | — | — | WO | disclosed |
| US-6006753-A | THERAPY | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0964873-A1 | USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0964692-A1 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0946191-A1 | USE OF GLP-1 ANALOGS AND DERIVATIVES ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY | ELI LILLY AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998019698-A1 | USE OF GLP-1 ANALOGS AND DERIVATIVES ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY | ELI LILLY AND COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998008531-A1 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998008873-A1 | USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5512549-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0708179-A2 | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |